Evidence map›Paper›PMID 36579704›Full record

ArticleQuality management in health care

Combined Symptom Screening and At-Home Tests for COVID-19.

Farrokh Alemi, Jee Vang, Wejdan Hassan Bagais, Elina Guralnik, Janusz Wojtusiak, F Gerard Moeller, Josh Schilling, Rachele Peterson, Amira Roess, Praduman Jain

Open access · greenAbstract read
In one paragraph

Article in Quality management in health care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 4 countries.

Farrokh AlemiVibrent Health, Inc, Fairfax, Virginia (Messrs Schilling and Jain and Ms Peterson); George Mason University, Fairfax, Virginia (Drs Alemi, Vang, Wojtusiak, and Roess and Mss Bagais and Guralnik); and Virginia Commonwealth University, Richmond, Virginia (Dr Moeller).ORCID 0000-0002-7402-9063
Wejdan Hassan Bagais
Janusz Wojtusiak
F Gerard Moeller
Rachele Peterson
Praduman Jain
Gaertner (United States) · US

Funding

Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
DIGITAL HEALTH SOLUTIONS FOR COVID-19: COVID COMMUNITY ACTION AND RESEARCH ENGAGEMENT (COVID-CARE)75N91020C00038 · NCI · VIGNET, INC. · PI JAIN, PRADUMAN · 2020 to 2021
$4.0M
NCATS NIH HHS UL1 TR002649NCI NIH HHS 75N91020C00038
6 · The paper itself

Abstract

BACKGROUND AND

objectiveAt-home rapid antigen tests provide a convenient and expedited resource to learn about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection status. However, low sensitivity of at-home antigen tests presents a challenge. This study examines the accuracy of at-home tests, when combined with computer-facilitated symptom screening.

methodsThe study used primary data sources with data collected during 2 phases at different periods (phase 1 and phase 2): one during the period in which the alpha variant of SARS-CoV-2 was predominant in the United States and another during the surge of the delta variant. Four hundred sixty-one study participants were included in the analyses from phase 1 and 374 subjects from phase 2. Phase 1 data were used to develop a computerized symptom screening tool, using ordinary logistic regression with interaction terms, which predicted coronavirus disease-2019 (COVID-19) reverse transcription polymerase chain reaction (RT-PCR) test results. Phase 2 data were used to validate the accuracy of predicting COVID-19 diagnosis with (1) computerized symptom screening; (2) at-home rapid antigen testing; (3) the combination of both screening methods; and (4) the combination of symptom screening and vaccination status. The McFadden pseudo-R2 was used as a measure of percentage of variation in RT-PCR test results explained by the various screening methods.

resultsThe McFadden pseudo-R2 for the first at-home test, the second at-home test, and computerized symptom screening was 0.274, 0.140, and 0.158, respectively. Scores between 0.2 and 0.4 indicated moderate levels of accuracy. The first at-home test had low sensitivity (0.587) and high specificity (0.989). Adding a second at-home test did not improve the sensitivity of the first test. Computerized symptom screening improved the accuracy of the first at-home test (added 0.131 points to sensitivity and 6.9% to pseudo-R2 of the first at-home test). Computerized symptom screening and vaccination status was the most accurate method to screen patients for COVID-19 or an active infection with SARS-CoV-2 in the community (pseudo-R2 = 0.476).

conclusionComputerized symptom screening could either improve, or in some situations, replace at-home antigen tests for those individuals experiencing COVID-19 symptoms.

Indexed as

COVID-19COVID-19 TestingHumansSARS-CoV-2Sensitivity and Specificity

Identifiers

PMID36579704
PMCPMC9811480
OpenAlexW4313312587

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.